Every 10-Q that LifeStance Health Group, Inc. (LFST) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow LFST and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LFST filings page.
LifeStance Health Group, Inc., a mental health services provider, reported strong growth for the quarter ended June 30, 2026. Total revenue was $435,354 (in thousands), a 26% increase year over year, driven by 2.6 million visits, higher total revenue per visit and a net increase of 834 clinicians to 8,542.
Income from operations was $30,653 (in thousands), compared with a loss from operations in the prior-year period, and net income reached $23,612 (in thousands), or $0.06 diluted earnings per share. Center Margin was $153,041 (in thousands) and Adjusted EBITDA was $66,042 (in thousands), reflecting improved scale and cost control.
For the first six months of 2026, cash provided by operating activities rose to $133,021 (in thousands), supporting acquisitions of three outpatient practices and share repurchases of $97,625 (in thousands). Cash and cash equivalents were $225,943 (in thousands) and term loan principal outstanding was $275,500 (in thousands) as of June 30, 2026.
LifeStance Health Group reported strong Q1 performance, with total revenue rising 21% to $403,476, driven by higher patient service revenue from a larger clinician base and more visits. Income from operations increased to $22,284, and net income improved sharply to $14,243, or $0.04 per diluted share.
Adjusted EBITDA reached $51,110, supported by 2.5 million patient visits and 8,349 employed clinicians as of March 31, 2026. The company generated $33,109 of operating cash flow, repurchased 7,000 shares for $49,107, and ended the quarter with $194,797 in cash. Previously identified material weaknesses in internal control over financial reporting remain unresolved, so disclosure controls are still not effective.
LifeStance Health Group (LFST) reported higher Q3 2025 results. Total revenue reached $363.8 million, up from $312.7 million a year ago. Income from operations was $7.4 million versus $0.05 million, and net income was $1.1 million compared with a prior-year net loss. For the first nine months, revenue was $1.04 billion and net loss narrowed to $2.0 million.
Cash and cash equivalents were $203.9 million, and net cash provided by operating activities rose to $88.6 million for the nine-month period. Long-term debt, net, was $269.4 million. Q3 Center Margin was $116.6 million and Adjusted EBITDA was $40.2 million. The company remained in compliance with debt covenants.
Commercial payors represented 90% of Q3 revenue, with government at 5% and self-pay at 4%. The interest rate swap matured on September 30, 2025. As of October 29, 2025, 389,000,281 common shares were outstanding.